Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121714243> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2121714243 endingPage "1692" @default.
- W2121714243 startingPage "1688" @default.
- W2121714243 abstract "Prostacyclin (PG) remains the gold standard therapy for severe pulmonary arterial hypertension (PAH). Previously, we reported the successful transitioning of PAH subjects from intravenous prostacyclin to oral bosentan (Suleman et al. Chest 2004;126:808-15). We report here the 5-year follow-up data.In the transition study, 11 PAH subjects were successfully transitioned to oral bosentan in 12 weeks. Two subjects who subsequently developed liver function test (LFT) abnormalities were taken off bosentan and switched to another endothelin receptor antagonist. Demographics, six-minute walk distance (6MWD), WHO functional class (FC), and survival data was collected.10 Females and 1 male ranging in age from 35 to 79 were successfully transitioned. Mean duration of illness prior to transition was 50.55+/-26 months. Mean duration that these subjects remained on oral therapy was 34+/-24 months. Mean duration that patients remained off PG was 28+/-21 months. In 7 of the 11 subjects (64%), PG was resumed due to clinical deterioration. One patient remained on bosentan as monotherapy, five had phosphodiesterase 5-inhibitor added. 9 Of the 11 subjects were WHO FC II post-transition and 5 of the 7 subjects at follow-up were WHO FC II (82% vs 67%). Post-transition 6MWD was 386+/-85 in 10 subjects and at follow-up 6MWD was 396+/-99 in 9 subjects (p=0.81).In this study, patients frequently required prostanoid resumption after transition from intravenous prostanoid to oral therapy. However, in these carefully selected patients, transition to oral therapy offered prolonged stable FC and 6MWD, cost savings and substantial quality of life benefits." @default.
- W2121714243 created "2016-06-24" @default.
- W2121714243 creator A5078442510 @default.
- W2121714243 date "2009-11-01" @default.
- W2121714243 modified "2023-09-24" @default.
- W2121714243 title "Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan" @default.
- W2121714243 cites W1986060795 @default.
- W2121714243 cites W1988773573 @default.
- W2121714243 cites W2028429430 @default.
- W2121714243 cites W2048443661 @default.
- W2121714243 cites W2051069436 @default.
- W2121714243 cites W2053680109 @default.
- W2121714243 cites W2070485900 @default.
- W2121714243 cites W2075537770 @default.
- W2121714243 cites W2090213540 @default.
- W2121714243 cites W2097487882 @default.
- W2121714243 cites W2121376498 @default.
- W2121714243 cites W2143183313 @default.
- W2121714243 cites W2148225708 @default.
- W2121714243 cites W2168080476 @default.
- W2121714243 cites W2321522617 @default.
- W2121714243 doi "https://doi.org/10.1016/j.rmed.2009.05.009" @default.
- W2121714243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19539456" @default.
- W2121714243 hasPublicationYear "2009" @default.
- W2121714243 type Work @default.
- W2121714243 sameAs 2121714243 @default.
- W2121714243 citedByCount "16" @default.
- W2121714243 countsByYear W21217142432013 @default.
- W2121714243 countsByYear W21217142432014 @default.
- W2121714243 countsByYear W21217142432017 @default.
- W2121714243 countsByYear W21217142432018 @default.
- W2121714243 countsByYear W21217142432020 @default.
- W2121714243 countsByYear W21217142432021 @default.
- W2121714243 crossrefType "journal-article" @default.
- W2121714243 hasAuthorship W2121714243A5078442510 @default.
- W2121714243 hasBestOaLocation W21217142431 @default.
- W2121714243 hasConcept C126322002 @default.
- W2121714243 hasConcept C141071460 @default.
- W2121714243 hasConcept C144980905 @default.
- W2121714243 hasConcept C164705383 @default.
- W2121714243 hasConcept C170493617 @default.
- W2121714243 hasConcept C2776345702 @default.
- W2121714243 hasConcept C2778266237 @default.
- W2121714243 hasConcept C2781109936 @default.
- W2121714243 hasConcept C2781128415 @default.
- W2121714243 hasConcept C71924100 @default.
- W2121714243 hasConceptScore W2121714243C126322002 @default.
- W2121714243 hasConceptScore W2121714243C141071460 @default.
- W2121714243 hasConceptScore W2121714243C144980905 @default.
- W2121714243 hasConceptScore W2121714243C164705383 @default.
- W2121714243 hasConceptScore W2121714243C170493617 @default.
- W2121714243 hasConceptScore W2121714243C2776345702 @default.
- W2121714243 hasConceptScore W2121714243C2778266237 @default.
- W2121714243 hasConceptScore W2121714243C2781109936 @default.
- W2121714243 hasConceptScore W2121714243C2781128415 @default.
- W2121714243 hasConceptScore W2121714243C71924100 @default.
- W2121714243 hasIssue "11" @default.
- W2121714243 hasLocation W21217142431 @default.
- W2121714243 hasLocation W21217142432 @default.
- W2121714243 hasOpenAccess W2121714243 @default.
- W2121714243 hasPrimaryLocation W21217142431 @default.
- W2121714243 hasRelatedWork W1989543455 @default.
- W2121714243 hasRelatedWork W2001451182 @default.
- W2121714243 hasRelatedWork W2003413015 @default.
- W2121714243 hasRelatedWork W2029198469 @default.
- W2121714243 hasRelatedWork W2094417002 @default.
- W2121714243 hasRelatedWork W2121714243 @default.
- W2121714243 hasRelatedWork W2146278091 @default.
- W2121714243 hasRelatedWork W2154606918 @default.
- W2121714243 hasRelatedWork W2171240223 @default.
- W2121714243 hasRelatedWork W2410332016 @default.
- W2121714243 hasVolume "103" @default.
- W2121714243 isParatext "false" @default.
- W2121714243 isRetracted "false" @default.
- W2121714243 magId "2121714243" @default.
- W2121714243 workType "article" @default.